NCT00605306View on ClinicalTrials.gov

Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Asthma
Interventions
DRUG

indacaterol maleate / mometasone furoate

Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.

DRUG

placebo to indacaterol maleate/mometasone furoate

Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.

Trial Locations (3)

Unknown

Novartis Investigator Site, Neuil

Novartis Investigator Site, Paris

Novartis Investigator Site, Poitiers

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Novartis

INDUSTRY

NCT00605306 - Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma | Biotech Hunter | Biotech Hunter